G-FACTOR
G-Factor is a reaction environment, which seeks to transform the potential for technological innovation that lies in young people and in scientists, into entrepreneurial realities able to successfully establish themselves in the market, creating replicable and scalable business models.
It is a response to address the need to integrate scientific research, industry and the market, focusing on young people and their business ideas.
Located in a one-of-a-kind territorial ecosystem with a strong scientific and entrepreneurial history, G-Factor aims to enable new entrepreneurs to grow, with an understanding approach following scientific and market principles, and with the support of personalized incubator and accelerator programs, access to capital, structures, and relationships.
Call Life Science - Apply Before 10/31/2019
The call, in its 2nd edition, is aimed at newcos, spinoffs and innovative startups, students, graduates and research doctorates, acting individually or in teams - belonging to public and private entities. Participating teams must have at least one team member under the age of 40.
The projects must be characterized by a strong mission in technology transfer and propose highly innovative therapeutic solutions for which an experimental proof of concept has already been completed in one of the following sectors: pharma, biotech, medtech, bioinformatics and bioengineering.
Roadshow presentazione call
Evento
Impresa
Evento
Impresa
Evento
Impresa
G-FORCE
An innovative program custom designed for researchers and young experts with a high technical-scientific profile, that accelerates individual and team talent and enables growth, both entrepreneurially and scientifically. The G-Force program has a total duration of 9 months with an initial residential phase of intensive activities of 3 months and a non-residential phase the following 6 months, which include workshops, mentoring, coaching, recruitment aid, matching of potential industry partners, combined with logistic services, business services, concessionary agreements and incentives. Accommodation in Bologna at affiliated structures for up to 2 team members is included for the first three months of the program.
WELCOME KIT
- Accommodation in Bologna
- Laboratories
- Instrumentation
- Business assessment
- Custom" G Force "program
Mentors
Alessandro Rizzoli
Founder
GetConnected
Andrea Cavalli
Coordinatore Dottorato in Data science and computation
Università di Bologna
ANTONELLA GRASSIGLI
Co-Founder & CEO | Angel Investor
Doorway Srl
Antonio Falcone
Amministratore Delegato
Principia SGR
Bernardo Balboni
Contamination Lab Chief
Unimore
Bill Morrow
Founder
Angels Den
Daniele Gazzola
President, CTO & Founder
CellDynamics
Diego Ardigo
R&D Rare Diseases Unit Head
Chiesi Group
Edoardo David
Investment Analyst
Mamacrowd
Enrico di Oto
CEO
OaCP
Filippo Cipriani
Head of Open Innovation Projects
Sanofi Genzyme
Francesco Bonvicini
Corporate HR Director
Alfasigma
Gianluca Sferrazza
Assegnista di Ricerca
CNR
Giovanni Trombetti
Commercialista
Studio Trombetti
Giuliana Gavioli
Head of Regulatory Affairs
B. Braun Avitum Ag
Henry Xu
Senior Fellow
The Wharton School
-LEONARDO GIAGNONI
Investment Manager
IAG
LORENZO MASSA
Chair in Corporate Strategy & Innovation
EPFL
LUCA FORESTI
CEO
Centro Medico Santagostino
LUCA ROSSETTINI
CEO & Founder
D-Orbit
LUCA SPACCAPELO
Head of Opportunity Evaluation Group
Chiesi Group
MARCELLA GUBITOSA
Co-Founder & CEO
Stars & Cows
MARCO GIACOMELLO
Co-Founder & Head of Legal Division
Makemark Company
MARCO MAZZONI
Owner
Ygoss Srl Consulting
MATTEO VIGNOLI
Director Open Innovation Program
Almacube
MAURIZIO MATRONE
Coach di narrativa d’impresa,
innovazione & creatività
Mavi Gianni
Attrice & Formatrice
Facilitatrice
MICHELE BARLETTA
Sales & Marketing Lead
Sanofi Genzyme
PAOLO SIVIERO
Senior Advisor & Fund Manager
Principia SGR
PASQUALE PIERIMARCHI
Chief Scientific Manager
Istituto di Farmacologia
Traslazionale, CNR
SARA BATTISTONI
HR Consultant
Stars & Cows
SIMONE FERRIANI
Professor
University of Bologna
STEVE GEDEON
Entrepreneurship Professor & Angel Investor
Ryerson
VALENTINA DE MATTEO
Innovation & Change Management Senior Consultant
Bip - Business Integration Partners
Portfolio
BCI is a biotechnological startup focused on maximizing the biocompatibility of cardiac valve substitutes manufactured with animal tissues improving their performance and doubling the duration of operation over time.
sito web
Adam’s Hand is a myoelectric hand prosthesis, based on a patent-pending mechanism that allows to move all the fingers with just one motor, making them automatically adapt to the grasped object shape and dimension.
sito web
Complexdata has developed a platform that uses artificial intelligence to estimate the risk of metastasis in a cancer patient. In addition to precision medicine, the platform can be used for the research and development of new drugs and the repositioning of older ones.
sito web
Diamante (Nano-Technologies for Autoimmune Disease Diagnosis) is an innovative startup with a strong social focus, led by a female team, specializing in the production of nanoparticles for the diagnosis of autoimmune diseases using biotech technologies based on the exploitation of plants as high value-added compounds.
sito web
eVai is the cloud platform of enGenome, developed to support medical geneticists in the diagnosis of hereditary diseases using NGS data analysis. Using Artificial Intelligence, eVAI provides the most accurate interpretation of genomic mutations.
sito web
Genoa Instruments is a spin-off of the Istituto Italiano di Tecnologia pioneering new technologies in the field of super-resolution optical microscopy, making them accessible for public and private research as well as for the industrial sector.
sito web
P4P S.r.L. produces innovative polymeric biomaterials processed with additive manufacturing techniques for the use of advanced drug delivery systems, improving and personalizing patient therapy.
Holey has created an integrated solution capable of producing custom-made orthopedic braces, for the fabrication of 3D printable orthotics, which can replace traditional plaster casts and commercial braces.
RELIEF S.r.L. proposes to engineer and bring to market a highly innovative device to combat severe urinary incontinence, providing a minimally invasive intraurethral insertion, activated with a small magnet.
MgShell is developing an intraocular drug delivery system for the treatment of maculopathy capable of releasing the right dose for the entire treatment, reducing the therapeutic load to a single injection.
Team
Ing. Antonio Danieli
Director General and Board Member
@ Fondazione Golinelli
CEO @ G-Factor Incubator-Accelerator
Dott.ssa Cristiana Vignoli
Director @ G-Factor Incubator-Accelerator
c.vignoli@fondazionegolinelli.it
